CN Patent

CN105753944B — 达卡他韦及其衍生物的制备中间体

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2019-10-01 · 7y expired

What this patent protects

本发明属于药物化学领域，具体涉及达卡他韦及其衍生物的制备中间体，以及它们的制备方法。该制备方法不仅简化了后处理过程，还出乎意料地提高每步反应的收率，进而提高了路线的总收率。此外，还提高了原料的利用率，节约成本，更适应工业化大生产。

USPTO Abstract

本发明属于药物化学领域，具体涉及达卡他韦及其衍生物的制备中间体，以及它们的制备方法。该制备方法不仅简化了后处理过程，还出乎意料地提高每步反应的收率，进而提高了路线的总收率。此外，还提高了原料的利用率，节约成本，更适应工业化大生产。

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN105753944B
Jurisdiction: CN
Classification: —
Expires: 2019-10-01
Drug substance claim: No
Drug product claim: No
Assignee: Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.